Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Common Equity: 2016-2019

Historic Common Equity for Monopar Therapeutics (MNPR) over the last 4 years, with Dec 2019 value amounting to $12.6 million.

  • Monopar Therapeutics' Common Equity rose 278.20% to $17.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.5 million, marking a year-over-year increase of 278.20%. This contributed to the annual value of $12.6 million for FY2019, which is 82.53% up from last year.
  • Monopar Therapeutics' Common Equity amounted to $12.6 million in FY2019, which was up 82.53% from $6.9 million recorded in FY2018.
  • Over the past 5 years, Monopar Therapeutics' Common Equity peaked at $12.6 million during FY2019, and registered a low of $2.8 million during FY2016.
  • For the 3-year period, Monopar Therapeutics' Common Equity averaged around $9.7 million, with its median value being $9.6 million (2017).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 239.78% in 2017, then fell by 28.08% in 2018.
  • Yearly analysis of 4 years shows Monopar Therapeutics' Common Equity stood at $2.8 million in 2016, then spiked by 239.78% to $9.6 million in 2017, then declined by 28.08% to $6.9 million in 2018, then surged by 82.53% to $12.6 million in 2019.